11/16
08:36 am
bcda
BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023) [Yahoo! Finance]
Medium
Report
BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023) [Yahoo! Finance]
11/14
01:34 pm
bcda
BioCardia, Inc. (NASDAQ: BCDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Medium
Report
BioCardia, Inc. (NASDAQ: BCDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
11/14
02:31 am
bcda
BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... [Yahoo! Finance]
High
Report
BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... [Yahoo! Finance]
11/13
04:22 pm
bcda
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results [Yahoo! Finance]
High
Report
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results [Yahoo! Finance]
11/13
04:05 pm
bcda
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
High
Report
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results
11/6
07:00 am
bcda
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
Low
Report
BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
10/28
11:18 am
bcda
BioCardia, Inc. (NASDAQ: BCDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
BioCardia, Inc. (NASDAQ: BCDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
10/28
09:00 am
bcda
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
Low
Report
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
9/18
08:30 am
bcda
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
High
Report
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
9/9
04:05 pm
bcda
BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Medium
Report
BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
8/30
08:00 am
bcda
BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Medium
Report
BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
8/29
09:28 am
bcda
BioCardia shares climb as it gets FDA clearance for its Morph DNA product family Aug. 29, 2024 9:07 AM ET By: Akanksha Khushi , SA News Editor [Seeking Alpha]
Medium
Report
BioCardia shares climb as it gets FDA clearance for its Morph DNA product family Aug. 29, 2024 9:07 AM ET By: Akanksha Khushi , SA News Editor [Seeking Alpha]
8/29
08:30 am
bcda
BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
Medium
Report
BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family